STRATA ADVISES THE SHAREHOLDERS OF MELBOURN SCIENTIFIC LIMITED ON ITS SALE TO INTERTEK GROUP PLC
Strata Partners is pleased to announce that it has acted as exclusive financial adviser to the shareholders of Melbourn Scientific Limited (“Melbourn”) on its sale to Intertek Group plc (“Intertek”), a leading quality solutions provider to industries worldwide.
Melbourn, a specialist pharmaceutical products testing business, is a privately owned UK company based near Cambridge where it employs over 80 scientists and staff. The company has built a strong reputation over the last 24 years providing expert testing and formulation services to the international pharmaceutical industry, with a focus on the testing and evaluation of nasally and orally inhaled drugs and their delivery systems such as inhalers and nebulisers.
Stephen Westcott, Founder and Chairman of Melbourn commented:
“We are delighted with the outcome that Strata helped us achieve. Strata’s understanding of the pharma services and lab testing sector and global relationships were instrumental in helping us achieve a great outcome for Melbourn and its shareholders.”
Mark Sargeant, Partner, Strata Partners commented:
“Melbourn is a world-leader in pharmaceutical development and analysis services for nasal and orally inhaled drugs. We were very pleased to assist the company, its founders and shareholders in achieving the sale to Intertek. This is the 14th successful M&A transaction we have acted on in the life science services and laboratory testing space and further evidences our position as Europe’s leading corporate finance advisory boutique in these fields.”